Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Biohaven drug re ALS to be tested at Mass General

An experimental ALS drug being developed in New Haven will be tested next year in a first-of-its-kind clinical trial led by Massachusetts General Hospital. Biohaven Pharmaceuticals’...

| By Kelley Gipson

Bayer and Arvinas in protein degradation venture

Bayer and Arvinas have launched a new company, Oerth Bio, to leverage Arvinas’ expertise in targeted protein degradation and Bayer’s experience in developing human therapies and...

| By Kelley Gipson

FDA grants breakthrough status to Achillion drug

Achillion Pharmaceuticals reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients...

| By Kelley Gipson

2019 Entrepreneur of the Year nominations open

BioCT invites your nominations for the 2019 Entrepreneur of the Year Award. The Entrepreneur of the Year Award was established by BioCT and Shipman and...

| By Kelley Gipson

SpringWorks reports orphan drug designation

SpringWorks reports that the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft...

| By Kelley Gipson

Is 100 the new 50? JAX studies aging

Researchers at The Jackson Laboratory are using genomic technologies and specialized mouse models to decipher the changes that occur as a consequence of aging in...

| By Kelley Gipson

UConn researchers to continue work on tapeworm

As a result of a recent large-scale global survey, tapeworms, a class which encompasses more than 5,000 species, are now one of the most well-known...

| By Kelley Gipson

New Haven emerges as biopharma city

Thirty years ago, the idea of starting a biotech venture in Connecticut was rare, if not unheard of. The obvious biotech hotbeds in the United...

| By Kelley Gipson

BioXcel to study role for Apple Watch re agitation

BioXcel Therapeutics has announced a strategic plan to investigate the development of using wearable digital device technology, such as the Apple Watch, with the goal of...